How Long Has Ozempic Been Around? The Full Timeline From 2008 Discovery to 2026

Key Takeaways

• Ozempic (semaglutide) was approved by the FDA on December 5, 2017, making it about 8 years old as of April 2026.
• The molecule itself was first synthesized in 2008 by Novo Nordisk researchers as a longer-acting successor to liraglutide.
• The first major Phase 3 trial (SUSTAIN 1) was published in 2017, the same year as approval.
• Ozempic was approved for type 2 diabetes only. Wegovy (the same molecule at higher doses) received separate FDA approval for chronic weight management in June 2021.
• By 2023 Ozempic had become the highest-grossing prescription drug in the world, with global sales exceeding $13.8 billion that year.

Direct answer (40-60 words)

Ozempic was approved by the U.S. Food and Drug Administration on December 5, 2017, so it has been on the market for about 8 years as of 2026. Its active ingredient, semaglutide, was first synthesized in a Novo Nordisk lab in 2008. Wegovy, the same drug at higher doses for weight loss, came in June 2021.

Table of contents

1. The 30-second answer
2. Full Ozempic development timeline (2008 to 2026)
3. The science behind the original 2008 discovery
4. Phase 1, 2, and 3 trials: what was tested before approval
5. The December 2017 FDA approval and what it covered
6. The 2021 Wegovy approval and the weight-loss expansion
7. Cardiovascular and kidney indications added since 2017
8. Ozempic vs older GLP-1 drugs: how the timeline compares
9. Manufacturing, shortages, and the compounding response
10. Where the drug stands today
11. FAQ

Full Ozempic development timeline (2008 to 2026)

The shortest version: semaglutide was synthesized in 2008, entered human trials in 2012, finished Phase 3 in 2016, was approved for diabetes in December 2017, and approved for weight loss (as Wegovy) in June 2021.

The longer version, year by year:

So the headline answer of "Ozempic has been around since December 2017" is accurate, but the molecule has roughly 18 years of development history behind it and the broader semaglutide brand has been generating clinical data continuously since 2012.

The science behind the original 2008 discovery

Native human GLP-1 (glucagon-like peptide-1) is a hormone secreted by L-cells in the small intestine after a meal. It tells the pancreas to release insulin, suppresses glucagon, slows gastric emptying, and dampens appetite. The trouble with native GLP-1 as a drug is that the enzyme DPP-4 chops it up within about 2 minutes of release, so any therapeutic effect would require continuous infusion.

Researchers spent the 1990s and 2000s designing GLP-1 analogs that resisted DPP-4. Exenatide, a synthetic version of a hormone from Gila monster saliva, was the first to reach the market in 2005. Liraglutide followed in 2010, with a half-life of about 13 hours allowing once-daily dosing.

Semaglutide, designed in 2008, took the engineering further. Novo Nordisk's chemists made three modifications:

1. Substituted alanine at position 8 with alpha-aminoisobutyric acid, blocking DPP-4 cleavage.
2. Substituted lysine at position 34 with arginine, preventing unwanted cross-linking.
3. Attached an 18-carbon fatty diacid chain to the lysine at position 26, which binds tightly to serum albumin in the bloodstream.

The albumin binding was the trick that pushed the half-life from hours to days. Semaglutide's plasma half-life of about 165 hours (around 7 days) is what allows once-weekly dosing.

This chemistry was first described in detail in a 2015 paper (Lau et al., Journal of Medicinal Chemistry).

Phase 1, 2, and 3 trials: what was tested before approval

Like every drug, semaglutide had to pass three stages of human testing before the FDA would approve it.

Phase 1 (2012 to 2013): small studies in healthy volunteers and people with type 2 diabetes confirmed the half-life, identified the dose range, and ruled out short-term safety signals. Phase 1 enrolled fewer than 100 people total.

Phase 2 (2013 to 2014): dose-finding studies established 0.5 mg and 1 mg as the doses that maximized A1c reduction with manageable side effects. The most common adverse event was nausea, particularly during titration.

Phase 3 (2013 to 2016): the SUSTAIN program. Ten randomized trials in roughly 9,500 patients with type 2 diabetes. Key results:

• SUSTAIN 1 (vs placebo, monotherapy): A1c dropped 1.45% with 0.5 mg, 1.55% with 1 mg vs 0.02% with placebo (Sorli et al., Lancet Diabetes Endocrinol 2017).
• SUSTAIN 6 (cardiovascular outcomes, 3,297 patients with high cardiovascular risk): 26% relative reduction in non-fatal MI, non-fatal stroke, or cardiovascular death (Marso et al., NEJM 2016).
• SUSTAIN 7 (vs dulaglutide): semaglutide outperformed on both A1c and weight loss.

The SUSTAIN 6 cardiovascular outcomes data is what gave the FDA the basis to approve the drug with a clean cardiovascular safety profile, which mattered after the 2007 controversy over rosiglitazone.

The December 2017 FDA approval and what it covered

The FDA's December 5, 2017 approval letter authorized Ozempic for adults with type 2 diabetes mellitus, as an adjunct to diet and exercise to improve glycemic control. The approval included two doses (0.5 mg and 1 mg subcutaneous, weekly) and required a Risk Evaluation and Mitigation Strategy (REMS) for the boxed warning about thyroid C-cell tumors observed in rodent studies.

What the 2017 approval did NOT cover:

• Weight loss in patients without diabetes (that came with Wegovy in 2021).
• Cardiovascular event reduction (added later via label updates).
• Use in adolescents (added in 2023 for type 2 diabetes age 12 and older).
• Use in pregnancy or breastfeeding (still not recommended).
• Type 1 diabetes (not indicated, no benefit established).

Insurance coverage in 2018 was limited because most plans required a step-therapy protocol with metformin and an SGLT-2 inhibitor before approving a GLP-1 drug.

The 2021 Wegovy approval and the weight-loss expansion

By 2017, clinicians had already noticed that Ozempic patients lost meaningful weight. Novo Nordisk ran the STEP program (Semaglutide Treatment Effect in People with obesity), four Phase 3 trials testing higher-dose semaglutide (2.4 mg weekly) specifically for chronic weight management.

STEP 1 (Wilding et al., NEJM 2021) was the headline result:

• 1,961 adults without diabetes, BMI 30 or higher, or BMI 27 with at least one weight-related condition.
• 68 weeks of treatment.
• Mean weight loss: 14.9% with semaglutide 2.4 mg vs 2.4% with placebo.
• About 86% of semaglutide patients lost 5% or more body weight.

The FDA approved Wegovy on June 4, 2021. The product is the same molecule as Ozempic at a higher dose, dispensed in a different injection pen with different titration instructions.

The 2021 Wegovy approval is often what people remember as "when Ozempic became big," but technically the brand "Ozempic" has only ever been approved for type 2 diabetes. Off-label prescribing of Ozempic for weight loss is what fueled the 2022 to 2024 cultural moment.

Cardiovascular and kidney indications added since 2017

The FDA has expanded semaglutide's approved uses several times since 2017:

• January 2020: label updated to include "reduction of cardiovascular events" in adults with type 2 diabetes and established cardiovascular disease.
• March 2024: Wegovy approved for cardiovascular risk reduction in adults with overweight/obesity plus established CV disease (SELECT trial).
• January 2025: FLOW trial results led to a label update for kidney protection in adults with type 2 diabetes and chronic kidney disease (Perkovic et al., NEJM 2024).

These additions are not separate drugs. They are new approved uses of the same molecule, supported by new outcomes trials. Each addition expands which patients can get insurance coverage and which providers feel comfortable prescribing.

Ozempic vs older GLP-1 drugs: how the timeline compares

Ozempic was the third weekly GLP-1 to reach the U.S. market and the most clinically successful so far. The relevant comparators:

The market shifted decisively to weekly injections after Trulicity launched in 2014. Ozempic's combination of weekly dosing, larger A1c reduction than dulaglutide, and meaningful weight loss made it the dominant GLP-1 by 2020.

Manufacturing, shortages, and the compounding response

From late 2022 through 2024, Novo Nordisk could not manufacture enough Ozempic and Wegovy to meet U.S. demand. The FDA's drug shortage list officially included semaglutide injection products from August 2022 to October 2024.

During the shortage, federal law (FDCA section 503A and 503B) allowed state-licensed compounding pharmacies to prepare semaglutide for individual prescriptions. Compounded semaglutide is not FDA-approved and is not interchangeable with brand Ozempic or Wegovy.

The FDA removed semaglutide from the shortage list on October 2, 2024, then again confirmed resolution in February 2025. Compounding under 503A is now restricted to clinically necessary modifications (e.g., a documented allergy to an inactive ingredient in the brand product) per current FDA enforcement policy.

Where the drug stands today

As of April 2026:

• Ozempic is approved for type 2 diabetes in over 80 countries.
• Wegovy is approved for chronic weight management in over 50 countries.
• Global semaglutide sales exceeded $26 billion in 2025 across both brands.
• Novo Nordisk's manufacturing capacity has roughly tripled since 2022 with new production sites in North Carolina and Denmark.
• Generic semaglutide is not available. Patent protection on the molecule extends into the early 2030s in most major markets.

For a drug that has only been on the market for 8 years, semaglutide has reshaped the treatment of diabetes, obesity, cardiovascular disease, and (more recently) chronic kidney disease.

For more on related topics, see our GLP-1 mechanism guide and our semaglutide vs tirzepatide comparison.

FAQ

When did Ozempic come out? Ozempic was approved by the FDA on December 5, 2017, and reached U.S. pharmacies in early 2018. It has been commercially available for about 8 years as of April 2026.

How old is the active ingredient in Ozempic? Semaglutide was first synthesized by Novo Nordisk researchers in 2008. Phase 1 human trials began in 2012, and the molecule has been studied continuously for about 18 years.

Was Ozempic originally for weight loss? No. The 2017 approval was for type 2 diabetes only. The same molecule at a higher dose was later approved for weight loss as Wegovy in June 2021. Ozempic itself remains approved for diabetes and (since 2020) for cardiovascular risk reduction in diabetic patients.

When was Wegovy approved? Wegovy (semaglutide 2.4 mg) received FDA approval on June 4, 2021 for chronic weight management. A March 2024 label update added cardiovascular risk reduction in adults with overweight or obesity and established cardiovascular disease.

Why does it feel like Ozempic just got popular? Ozempic was approved in late 2017 but didn't enter mainstream cultural awareness until 2022 to 2023, when off-label prescribing for weight loss accelerated and Wegovy faced repeated shortages. The drug was working well in diabetes for 4 years before it became a household name.

Is Ozempic FDA-approved? Yes. The FDA approved Ozempic on December 5, 2017 for type 2 diabetes. The label has since been expanded to include cardiovascular event reduction in diabetic patients with established CV disease and (in some formulations) kidney protection.

How long do people typically stay on Ozempic? For type 2 diabetes, the drug is generally considered chronic therapy. Most patients continue indefinitely as long as it's effective and tolerated. Discontinuation typically results in regain of weight and worsening of A1c within 3 to 6 months.

Has Ozempic ever been recalled? No. As of April 2026, Ozempic has not been recalled in the United States. Counterfeit Ozempic pens have been seized at borders, and the FDA has issued public warnings about counterfeit products sold outside the legitimate supply chain.

When will generic Ozempic be available? Patent protection on semaglutide extends into the early 2030s in the U.S. and most major markets, so generic versions are not expected before then. Compounded semaglutide is not a generic and was a temporary response to FDA-declared shortages.

Did Ozempic come from research on a lizard? The first GLP-1 drug, exenatide (Byetta), was derived from a peptide in the saliva of the Gila monster. Ozempic's active ingredient, semaglutide, is a synthetic modification of human GLP-1, not the lizard peptide.

How does Ozempic compare to older diabetes medications? Ozempic produces larger A1c reductions than older oral agents like metformin or sitagliptin and outperformed daily liraglutide, weekly dulaglutide, and basal insulin in head-to-head SUSTAIN trials. It also produces meaningful weight loss, which most other diabetes drugs do not.

Is Ozempic safe for long-term use? The longest published continuous-use data extends to 4 years (SUSTAIN 6 long-term extension). The cardiovascular safety profile has remained favorable across that window. Long-term tolerance is generally good, with the main issues being GI side effects, gallbladder events, and a small pancreatitis signal.

Sources

1. Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes Endocrinol. 2017;5(4):251-260.
2. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
5. Perkovic V, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391:109-121.
6. Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58(18):7370-7380.
7. Kelly AS, et al. A randomized, controlled trial of liraglutide for adolescents with obesity (STEP TEENS update). N Engl J Med. 2020;382:2117-2128.
8. U.S. Food and Drug Administration. Ozempic (semaglutide) prescribing information. Approved December 5, 2017.
9. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. Approved June 4, 2021.
10. U.S. Food and Drug Administration. FDA Drug Shortage Database, semaglutide entries 2022-2024.
11. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2026;49(Suppl 1).
12. Novo Nordisk Annual Report 2024 and 2025 financial filings.
13. European Medicines Agency. Ozempic European public assessment report. Approved February 8, 2018.
14. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15-30.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity, Bydureon, Byetta, and Victoza are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.